LakeShore Biopharma
LSB was delisted on the 19th of September, 2025.
14 hedge funds and large institutions have $20.4M invested in LakeShore Biopharma in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
6.41% more ownership
Funds ownership: 0% → 6.41% (+6.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$21.8M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$13.8M |
| 3 |
VAM
Valliance Asset Management
Central,
Hong Kong
|
+$8.14M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.9M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$3.81M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $6.88M | +$21.8M | +429,846 | New |
|
|
2
Fidelity International
Hamilton,
Bermuda
| $4.35M | +$13.8M | +271,850 | New |
|
|
SLM
3
Snow Lake Management
Menlo Park,
California
| $2.9M | +$9.18M | +181,194 | New |
|
|
VAM
4
Valliance Asset Management
Central,
Hong Kong
| $2.57M | +$8.14M | +160,718 | New |
|
|
5
Fidelity Investments
Boston,
Massachusetts
| $1.86M | +$5.9M | +116,507 | New |
|
|
HA
6
HHLR Advisors
Grand Cayman,
Cayman Islands
| $1.2M | +$3.81M | +75,179 | New |
|
|
RI
7
RTW Investments
New York
| $546K | +$1.73M | +34,109 | New |
|
8
Millennium Management
New York
| $37K | +$117K | +2,309 | New |
|
|
FSI
9
Flow State Investments
Chicago,
Illinois
| $32K | +$101K | +2,000 | New |
|
10
Geode Capital Management
Boston,
Massachusetts
| $21.8K | +$69K | +1,361 | New |
|
11
Jane Street
New York
| $19.2K | +$60.7K | +1,197 | New |
|
|
PAM
12
Pinpoint Asset Management
Hong Kong
| $7.79K | +$253K | +5,000 | New |
|
|
WAM
13
Wolverine Asset Management
Chicago,
Illinois
| $798 | +$2.53K | +50 | New |
|
|
CS
14
Clear Street
New York
| $160 | +$507 | +10 | New |
|
LSB Hedge Fund Activity: Q1 2023 in Review
14 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma (LSB) for Q1 2023, worth a combined $20.4M.
Buyers outnumbered sellers: 14 funds opened new LSB positions and 0 closed out — a net gain of 14 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $21.8M.
- 14 institutional investors held LakeShore Biopharma (LSB) as of Q1 2023, up from 0 in Q4 2022.
- Funds reported $20.4M of LakeShore Biopharma stock for Q1 2023.
- 14 funds opened new LakeShore Biopharma positions in Q1 2023 and 0 closed out, a net change of +14 holders.
- The largest LakeShore Biopharma buyer in Q1 2023 was OrbiMed, an estimated $21.8M added.
Based on aggregated 13F filings for Q1 2023.